Progyny's Record Selling Season Outshines A Basis-Driven EPS Miss, But Margins Show Little Leverage

Progyny's third quarter registers as a sizable miss in the Earnings Whispers data, but the miss reflects a comparison of different bases more than an operating shortfall. Reported EPS of $0.32 fell 39.6% short of the $0.51 consensus and the $0.53 Earnings Whisper number, and earnings declined 22.0% year over year on the normalized basis. The $0.32 figure is GAAP diluted EPS, while the consensus was set on a non-GAAP basis. On the company's own adjusted measure, EPS was $0.52 versus $0.45 a year earlier, a penny above consensus and a penny below the whisper. GAAP EPS also more than doubled from $0.15. Revenue of $341.25 million rose 8.9% and beat consensus by 0.5%. Investors reading only the headline will see a miss. The quarter's real story is a record selling season that resets the 2027 growth runway.

The quality of the earnings growth deserves scrutiny. GAAP net income rose to $26.3 million from $13.9 million, driven largely by stock-based compensation falling to $21.1 million from $32.2 million. Adjusted net income rose only modestly, to $42.2 million from $40.8 million. Most of the adjusted EPS gain came from the buyback, which cut diluted shares to 81.2 million from 90.2 million. Reported gross margin widened to 24.5% from 23.2%, but excluding stock compensation it improved only to 26.5% from 26.2%. Adjusted EBITDA grew 6.3%, slower than revenue, and adjusted EBITDA margin slipped to 17.1% from 17.5% as the company kept investing in its platform. Fertility benefit services revenue grew 10.6%, while pharmacy revenue grew a slower 5.8%. Female utilization edged up to 0.49% from 0.47%. ART cycles per female utilizer, however, were 0.50 versus 0.52 a year ago, so treatment intensity remains softer.

The call shifted attention firmly toward 2027. Progyny sold a record 1.3 million new covered lives and added more than 85 clients, beating the 1 million-plus target reiterated last quarter by roughly 30%. Roughly 100,000 of those lives came in the final month alone. Wins include a second Magnificent Seven tech company, one of the largest U.S. banks, prominent universities and a large public-employee benefit fund. Retention was again near 100%, and pharmacy attach on new clients is near 100%. Management expects more than 660 clients and about 8.3 million covered lives once 2027 launches are complete, versus 7.2 million this year. It described its pipeline for next season as its largest ever. Management also said a second competitor is significantly pulling back after another exited a year ago, a meaningful shift in the competitive landscape.

Guidance moved up, but only modestly, and Earnings Whispers characterizes it as in-line:

• Full-year revenue: $1.365 billion to $1.385 billion, versus $1.36 billion to $1.385 billion previously. The high end remains below the $1.405 billion offered in the first quarter.
• Adjusted EBITDA: raised to $235 million to $240 million.
• Adjusted EPS: raised to $2.09 to $2.13, from $2.04 to $2.10.
• Fourth-quarter revenue: $344.7 million to $364.7 million.

The fourth-quarter range requires a sequential step-up after ART cycles were roughly flat sequentially in the third quarter.

Bears have legitimate ammunition beneath the record sales numbers. Several hundred thousand new lives launch mid-year, which defers their revenue contribution. The large public-sector client was underwritten at slightly lower utilization than the existing book. The share of the base adding services fell to about 20% for 2027 from 30% for 2026. Eligibility files are expected for just over half of lives by year-end, short of the earlier goal of a significant majority. Cash and marketable securities fell to $195.6 million from $236.9 million in June after $82.7 million of third-quarter repurchases. Only about $51 million remains on the current authorization, which limits how long buybacks can keep amplifying per-share growth. Management's reiteration that the investment cycle tapers through 2027 is the key offset, since it implies margin leverage that this quarter did not yet show.

The market had already been leaning into the story before the report. Shares rose 13.7% from the $25.56 open after the August report to $29.06. That leaves the stock about 19% above its 200-day moving average and 2.4% below the inter-earnings high of $29.76 set just two days before the release. The stock had rallied roughly 19% off its late-September low of $24.33. Investor sentiment moved from -0.167 to +0.065, a meaningful swing from mildly negative to slightly positive, though not outright enthusiasm. Momentum and AVWAP trend readings are positive. Together, the setup suggests investors entered the report already expecting good selling-season news.

The bottom line is that Progyny delivered the forward-looking evidence that matters most: record new lives, near-total retention, a weakening competitive field and a credible path to roughly 15% covered-life growth in 2027. The headline miss is largely a GAAP-versus-adjusted artifact. Still, adjusted profit growth leaned heavily on buybacks and lower stock compensation, margins were flat to down, and some of the new volume arrives late or at lower utilization. With shares near the top of their range, the next leg likely depends on margin leverage showing up as management says the investment cycle winds down.

Read our earnings preview for Progyny, Inc.: https://www.earningswhispers.com/article/PGNY/21907

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.